CLEANWATTS
11.8.2022 12:43:09 CEST | Business Wire | Press release
Cleanwatts, the leading climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world, presents Soma Demeny as VP of HR, assuming the responsibility of leading our most important assets: people .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005340/en/
Soma Demeny began his career in Deutsche Telekom, subsequently spending 17 years with General Electric (GE) where he led human resource teams in Finance, Digital and Corporate divisions. Soma’s international career is centered on helping service and manufacturing organizations scale, grow and adapt to change through the implementation of world-class human resource infrastructures and best practices. More recently, Soma directed much of his time and expertise to help smaller mid-market companies reorganize and adapt to change.
Soma carries degrees in Business Studies and Human Resources Management and is a graduate of GE’s prestigious Human Resources Leadership Program. Soma is Hungarian and has lived in the UK, Austria, and South America. Among Soma’s defining characteristics are curiosity, agility, creativity and fun. As a father of two and a company cultural ambassador, this remains a key philosophy for Soma.
When asked why he joined Cleanwatts, Soma replied pointedly: “Who wouldn’t want to be part of changing the world?”
Cleanwatts’ appointment of Soma Demeny is yet another important decision taken by the company in recent months. It reflects Cleanwatts’ commitment to building a healthy, vibrant and talented organization able to travel at market speed. Michael Pinto, Cleanwatts co-founder and CEO, describes Soma as “a world-class HR Leader, out-of-the-box thinker and a person that connects very easily with people through his critical thinking, emotional intelligence, and clear communication style.”
Soma will be responsible for designing and overseeing the company’s HR strategy, including recruitment and employee retention programs, evaluating and improving the company’s employee value proposition, training and development plans, as well as creating a safe workplace, healthy and inspirational culture as the organization continues to build a world in which clean energy is decentralized, digitalized, and democratized.
Ends
About Cleanwatts
We are a climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world. We achieve this by optimizing the consumption, generation, storage, trading, and balancing of clean energy, where it matters most: locally.
We deliver value by creating and managing Renewable Energy Communities, deploying our domain expertise, proprietary technology, financial capital, and management capabilities for the benefit of our clients.
At the heart of our offering stands Cleanwatts™ OS, our Operating System specifically designed to manage energy communities. Cleanwatts™ OS is a modular, interoperable, and localizable cloud-based platform that seamlessly connects the dots between behind-the-meter optimization for community members, front-of-the-meter grid resiliency, and transaction management for local energy markets.
We are now actively managing a growing list of over 100 energy communities built by our very own REC Factory: a highly skilled cross-functional team, committed to working closely with anchor clients, town halls, and other community members to develop the best solution for each local community that we serve. Building on the success of our first REC Factory in Portugal, we’re now replicating this level of engagement in other geographies around the world.
We are building a world in which clean energy is decentralized, digitalized, and democratized.
Follow Cleanwatts on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
